Ryan Stansfield

Ryan Stansfield has worked in various roles since 1998. Ryan started as a Chemistry and Biology Teacher for the Peace Corps in 1998. In 2002, they became a Scientist at the Schering-Plough Research Institute (NeoGenesis Pharmaceuticals acquired by SPRI in 2005). In 2006, they moved to Cylene Pharmaceuticals as a Senior Scientist. In 2012, they joined Celgene Quanticel Research (Quanticel Pharmaceuticals acquired by Celgene in 2015) as a Senior Scientist. In 2017, they were hired as a Senior Scientist at Jecure Therapeutics (Jecure acquired by Genentech in 2018). Most recently, in 2019, they were appointed as Associate Director at 858 Therapeutics.

Ryan Stansfield earned a B.S. in Zoology from UC Santa Barbara between 1993 and 1997.